Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.

Abstract:

:Fludarabine (FLUDA) based chemotherapy has shown promise in both initial and salvage treatment of low-grade non Hodgkin's lymphomas (LG-NHL). Recently, more aggressive therapies followed by autologous hemopoietic progenitor cell rescue, have also been successfully employed in these patients. However, this procedure, due to several factors including previous therapeutic regimens, is often limited by an inadequate collection of peripheral blood stem cell (PBSC). At present, very little data is available on the effect of FLUDA containing regimens in PBSC collection. We report our preliminary experience showing a possible correlation between FLUDA based chemotherapy regimens employed before mobilization and inability to collect an adequate number of blood derived hematopoietic progenitors for autologous PBSC transplantation in LG-NHL patients.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Laszlo D,Galieni P,Raspadori D,Scalia G,Bigazzi C,Bocchia M,Bucalossi A,Marotta G,Tozzi M,Lauria F

doi

10.3109/10428190009057639

keywords:

subject

Has Abstract

pub_date

2000-03-01 00:00:00

pages

157-61

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

37

pub_type

杂志文章
  • Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.

    abstract::A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051762

    authors: Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

    更新日期:1996-07-01 00:00:00

  • Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma.

    abstract::In this study cytogenetic findings have been correlated with prognosis in 78 previously untreated patients with non-Hodgkin's lymphoma (NHL) presenting between 1983 and 1988. The median follow-up was 7 years (range 2-9 years). There was no significant difference in the duration of survival of 33 patients with only abn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709039037

    authors: Juneja S,Matthews J,Lukeis R,Laidlaw C,Cooper I,Wolf M,Ironside P,Garson OM

    更新日期:1997-05-01 00:00:00

  • Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

    abstract::During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109060343

    authors: Lindauer M,Fischer T

    更新日期:2001-05-01 00:00:00

  • Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.738365

    authors: Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

    更新日期:2013-05-01 00:00:00

  • Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.

    abstract::Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500254299

    authors: Fox LP,Geyer AS,Husain S,Grossman ME

    更新日期:2006-01-01 00:00:00

  • The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and -5q31 in a human cell line.

    abstract::Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145730

    authors: Stillman WS,Varella-Garcia M,Irons RD

    更新日期:1999-10-01 00:00:00

  • Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia.

    abstract::Early and targeted antimicrobial therapy improves outcomes in patients with febrile neutropenia (FN). We evaluated the impact of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) on antimicrobial utilization in the management of FN. A cohort of patients with FN and hematological malignancy was iden...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.677533

    authors: Koh KC,Slavin MA,Thursky KA,Lau E,Hicks RJ,Drummond E,Wong PS,Worth LJ

    更新日期:2012-10-01 00:00:00

  • Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.

    abstract::In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one pat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600580817

    authors: Rodriguez V,Anderson PM,Litzow MR,Erlandson L,Trotz BA,Arndt CA,Khan SP,Wiseman GA

    更新日期:2006-08-01 00:00:00

  • Significance of circulating plasma cells in multiple myeloma.

    abstract::The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049709

    authors: Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

    更新日期:1994-08-01 00:00:00

  • Chronic lymphocytic leukemia complicated by plasmacytoma originating from different clones.

    abstract::In a woman with chronic lymphocytic leukemia (CLL), a plasmacytoma developed on the back region after four years. CLL cases complicated with plasmacytoma are rare. In the present case, the plasmacytoma showed kappa cytoplasmic immunoglobulin (Ig), and the CLL showed gamma lambda surface Ig. To reveal the clonal origin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053555

    authors: Yahata N,Iwase O,Iwama H,Tauchi T,Kawanishi Y,Serizawa H,Ohyashiki K

    更新日期:2000-09-01 00:00:00

  • Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.

    abstract::Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309147353

    authors: Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

    更新日期:1993-05-01 00:00:00

  • Treatment of multiple myeloma in the elderly: realities and hopes.

    abstract::Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and saf...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.530361

    authors: De La Rubia J,Sanz MA

    更新日期:2011-01-01 00:00:00

  • Changing landscape of frontline therapy in chronic lymphocytic leukemia.

    abstract::The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-ce...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1688321

    authors: Bhat SA,Woyach JA

    更新日期:2020-03-01 00:00:00

  • Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study.

    abstract::This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909050958

    authors: Dmoszyńska A,Legiec W,Wach M

    更新日期:1999-07-01 00:00:00

  • Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.

    abstract::Survival of chronic lymphocytic leukemia (CLL) cells in vivo is supported by the tissue microenvironment, which includes components of the extracellular matrix. Interactions between tumor cells and the extracellular matrix are in part mediated by CD44, whose principal ligand is hyaluronic acid. Here, we show that CD44...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.569962

    authors: Herishanu Y,Gibellini F,Njuguna N,Hazan-Halevy I,Farooqui M,Bern S,Keyvanfar K,Lee E,Wilson W,Wiestner A

    更新日期:2011-09-01 00:00:00

  • Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.

    abstract::Colony stimulating factors reduce the duration of neutropenia following intensive chemotherapy in a variety of settings, but the advantages in the management of leukemia are inconclusive. The variations in clinical results and the high costs of granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009057629

    authors: Bennett CL,Stinson TJ,Laver JH,Bishop MR,Godwin JE,Tallman MS

    更新日期:2000-03-01 00:00:00

  • Chromosomal instability and ATR amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL).

    abstract::Forty-three patients with persistent and polyclonal B-cell lymphocytosis (PPBL) were studied. The PPBL diagnosis was based on the presence of a polyclonal lymphocytosis and the detection of binucleated lymphoid cells on peripheral blood examination. In order to define the cytogenetic profile in these patients, convent...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194042000191738

    authors: Mossafa H,Tapia S,Flandrin G,Troussard X,Groupe Français d'Hématologie Cellulaire (GFHC).

    更新日期:2004-07-01 00:00:00

  • Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.

    abstract::Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols. We reviewed the progress and outcomes of 40 adolescents and adults up to 45 years of age, from three Australian centers, treated on the inte...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428194.2014.894191

    authors: Hocking J,Schwarer AP,Gasiorowski R,Patil S,Avery S,Gibson J,Iland H,Ho PJ,Joshua D,Muirhead J,Lai H,Irving I

    更新日期:2014-12-01 00:00:00

  • Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

    abstract::The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1613540

    authors: Stahl M,Tallman MS

    更新日期:2019-12-01 00:00:00

  • Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas.

    abstract::Primary central nervous system lymphoma (PCNSL) in immunocompetent patients is highly malignant and has a poor prognosis. The PCNSL molecular features are reminiscent to some degree of diffuse large B-cell lymphoma (DLBCL), yet PCNSL shows unique molecular profiles and a distinct clinical behavior. This article charac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903518329

    authors: Pedersen MØ,Hansen PB,Nielsen SL,Penkowa M

    更新日期:2010-02-01 00:00:00

  • Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma.

    abstract::Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058457

    authors: Ferreri AJ,Cordio S,Ponzoni M,Villa E

    更新日期:1999-05-01 00:00:00

  • Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.

    abstract::JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1509315

    authors: Menghrajani K,Boonstra PS,Mercer JA,Perkins C,Gowin KL,Weber AA,Mesa R,Gotlib JR,Wang L,Singer JW,Talpaz M

    更新日期:2019-04-01 00:00:00

  • Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.

    abstract::HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760011

    authors: Burke LP,Kukoly CA

    更新日期:2008-02-01 00:00:00

  • Differential effects of the MDR1 (multidrug resistance) gene-activating agents on protein kinase C: evidence for redundancy of mechanisms of acquired MDR in leukemia cells.

    abstract::Human leukemia cells may acquire MDR1/P-glycoprotein-mediated multidrug resistance (MDR) in the course of short-term (within hours) exposure to many stress stimuli. This effect is thought to be associated with the activity of protein kinase C (PKC) (Chaudhary, Roninson, 1992. 1993). However, we show here that cytosine...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009054896

    authors: Shtil AA,Ktitorova OV,Kakpakova ES,Holian O

    更新日期:2000-12-01 00:00:00

  • Induced apoptosis by mild hyperthermia occurs via telomerase inhibition on the three human myeloid leukemia cell lines: TF-1, K562, and HL-60.

    abstract::The purpose of this research was to understand the effect of hyperthermia on the telomerase activity in human leukemic cell lines (HL-60, K562, and TF-1). The cells were treated by hyperthermia at the range of 41-44 degrees C for 120 min and incubated for 96 h. Then telomerase activity, cell proliferation, and apoptos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190903129130

    authors: Deezagi A,Manteghi S,Khosravani P,Vaseli-Hagh N,Soheili ZS

    更新日期:2009-09-01 00:00:00

  • Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman.

    abstract::Adult T-cell leukemia/lymphoma (ATLL) remains an uncommon disorder outside well-defined risk groups. We describe the case of an Iranian woman, who presented with isolated meningeal relapse of diffuse large-cell lymphoma. The malignant cells coexpressed CD4 and CD8 and HTLV-1 seropositivity was confirmed. Despite combi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409073790

    authors: Seymour JF,Younes A,Cabanillas F

    更新日期:1994-02-01 00:00:00

  • Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

    abstract::Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1231405

    authors: Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Rojas L,Martínez-Cuadrón D,Hervás D,Boluda B,García-Robles A,Rodríguez-Veiga R,Martín-Cerezuela M,Cervera J,Sendra L,Sanz J,Miguel A,Lorenzo I,Poveda JL,Sanz

    更新日期:2017-05-01 00:00:00

  • Diversity in antibody-based approaches to non-Hodgkin lymphoma.

    abstract::Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for approximately 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that target CD20 antigens on the surface...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.500047

    authors: Maloney D,Morschhauser F,Linden O,Hagenbeek A,Gisselbrecht C

    更新日期:2010-08-01 00:00:00

  • Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

    abstract::Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864352

    authors: Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

    更新日期:2021-01-11 00:00:00

  • The late adverse events of rituximab therapy--rare but there!

    abstract::Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902934944

    authors: Ram R,Ben-Bassat I,Shpilberg O,Polliack A,Raanani P

    更新日期:2009-07-01 00:00:00